7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d23631766e169">The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. </p>

          Related collections

          Author and article information

          Contributors
          (View ORCID Profile)
          Journal
          New England Journal of Medicine
          N Engl J Med
          Massachusetts Medical Society
          0028-4793
          1533-4406
          September 23 2020
          Affiliations
          [1 ]From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (C.P.C.); AdventHealth Translational Research Institute, Orlando, FL (R.P.); the University of Tennessee Health Science Center, Memphis (S.D.-J.); Pfizer, Groton, CT (J.M., U.M., R.F., S.G.T.); Merck, Kenilworth, NJ (S.H., I.G.); the Department of Endocrinology, University of Nantes, Nantes, France (B.C.); Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, New Brunswick (W.J.S.); Pfizer...
          Article
          10.1056/NEJMoa2004967
          32966714
          4a1ea7c6-7b4a-4e1a-a4b5-1185a61b4b0d
          © 2020

          http://www.nejmgroup.org/legal/terms-of-use.htm

          History

          Comments

          Comment on this article